A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

TGI-6 Injection

TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.

Trial Locations (1)

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Hefei TG ImmunoPharma Co., Ltd.

OTHER